US-based healthcare company Aetna has signed a value-based contract with Merck for type 2 diabetes medications Januvia (sitagliptin) and Janumet (sitagliptin and metformin).

The contract aims to support the companies’ objectives to help adult patients with type 2 diabetes access appropriate treatment.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under the contract, Merck’s rebates on Januvia and Janumet medications will be based in part on the products’ contributions to help Aetna’s commercial member population with this diabetes achieve treatment objectives.

Merck global human health US market president Robert McMahon said: “Merck shares Aetna’s commitment to focusing on patients, and we are confident that the value-based agreement will help advance our common goal of helping patients with type 2 diabetes.”

"It is in everyone’s interest to ensure that patients receive appropriate medicines to help achieve their treatment goals."

Merck has additionally agreed to collaborate on Aetna’s new personalised health and wellness care initiative, known as AetnaCare.

The patient-centric approach to care identifies target populations using predictive analytics and provides the knowledge, tools, and support to members to help them take a proactive role in managing their own health.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Aetna executive vice-president and chief medical officer Dr Harold Paz said: “At Aetna, we believe that focusing on how physicians prescribe medications in real-world settings is a key element in determining the value of the treatment.

“It is in everyone’s interest to ensure that patients receive appropriate medicines to help achieve their treatment goals.”

The programme will initially target patients with diabetes and hypertension in mid-Atlantic markets.

Aetna will incorporate some of the educational resources from Merck’s inventory into AetnaCare to support effective patient self-management.